- Current status of endoscopic balloon dilation for Crohn's disease
-
Hirai F
- KMID: 2425157
- Intest Res.
- 2017 Apr;15(2):166-173.
- doi: 10.5217/ir.2017.15.2.166
The therapeutic target in Crohn's disease (CD) has been raised to the achievement of mucosal healing. Although effective treatments that target cytokines and other molecules has been widely used for... -
- CITED
-
- Close
- SHARE
-
- Close
- Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study
-
Nagata T, Funakoshi S, Morihara D, Shakado S, Yokoyama K, Takata K, Tanaka T, Fukunaga A, Yamauchi R, Fukuda H, Matsuoka H, Imakiire S, Sakisaka H, Matsuoka S, Kuno N, Abe K, Ishibashi H, Ashizuka S, Hirai F
- KMID: 2547197
- Intest Res.
- 2023 Oct;21(4):471-480.
- doi: 10.5217/ir.2023.00035
Background/Aims: The frequency and details of nonalcoholic fatty liver disease (NAFLD) complications in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to clarify characteristics of NAFLD in... -
- CITED
-
- Close
- SHARE
-
- Close
- Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
-
Koga A, Matsui T, Takatsu N, Takada Y, Kishi M, Yano Y, Beppu T, Ono Y, Ninomiya K, Hirai F, Nagahama T, Hisabe T, Takaki Y, Yao K, Imaeda H, Andoh A
- KMID: 2417674
- Intest Res.
- 2018 Apr;16(2):223-232.
- doi: 10.5217/ir.2018.16.2.223
BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis
-
Imakiire S, Takedatsu H, Mitsuyama K, Sakisaka H, Tsuruta K, Morita M, Kuno N, Abe K, Funakoshi S, Ishibashi H, Yoshioka S, Torimura T, Hirai F
- KMID: 2524766
- Gut Liver.
- 2022 Jan;16(1):92-100.
- doi: 10.5009/gnl210211
Background/Aims: Proteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) is a serologic marker for granulomatosis with polyangiitis. However, recent studies have also shown their role as diagnostic markers for ulcerative colitis (UC).... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
-
Hisamatsu , Kunisaki R, Nakamura S, Tsujikawa , Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M, CERISIER Trial group
- KMID: 2417663
- Intest Res.
- 2018 Jul;16(3):494-498.
- doi: 10.5217/ir.2018.16.3.494
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
-
Inoue N, Kobayashi , Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson A, Thakkar RB, Hibi T
- KMID: 2382384
- Intest Res.
- 2017 Jul;15(3):395-401.
- doi: 10.5217/ir.2017.15.3.395
BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk factors for severity of colonic diverticular hemorrhage
-
Kinjo K, Matsui T, Hisabe T, Ishihara H, Kojima T, Chuman K, Yasukawa S, Beppu T, Koga A, Ishikawa S, Kishi M, Takatsu N, Hirai F, Yao K, Ueki T, Washio M
- KMID: 2417658
- Intest Res.
- 2018 Jul;16(3):458-466.
- doi: 10.5217/ir.2018.16.3.458
BACKGROUND/AIMS: Colonic diverticular hemorrhage (DH) was a rare disease until the 1990s, and its incidence has increased rapidly since 2000 in Japan. In recent years, colonic DH has been the... -
- CITED
-
- Close
- SHARE
-
- Close
- Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study
-
Kim ES, Tae CH, Jung SA, Park DI, Im JP, Eun CS, Yoon H, Jang BI, Ogata H, Fukuhara K, Hirai F, Ohtsuka K, Liu J, Cao Q, on behalf of the Clinical Research Committee of the Asian Organization for Crohn’s and Colitis
- KMID: 2529565
- Intest Res.
- 2022 Apr;20(2):192-202.
- doi: 10.5217/ir.2020.00150
Background/Aims: Complementary and alternative medicine (CAM) is prevalent in East Asia. However, information on CAM in East Asian patients with inflammatory bowel disease (IBD) is scarce. We aimed to profile... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
-
Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M
- KMID: 2539010
- Intest Res.
- 2023 Jan;21(1):110-125.
- doi: 10.5217/ir.2021.00143
Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
